SIPULEUCEL-T
Total Payments
$588,020
Transactions
5
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $588,020 | 5 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $588,020 | 5 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| IISInman-George | Valeant Pharmaceuticals North America LLC | $276,444 | 1 |
| IIS InmanGeorge | Valeant Pharmaceuticals North America LLC | $138,222 | 1 |
| IIS Antonarakis | Valeant Pharmaceuticals North America LLC | $129,275 | 1 |
| IIS Rosser | Valeant Pharmaceuticals North America LLC | $44,079 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $588,020
- Total Doctors 3
- Transactions 5
About SIPULEUCEL-T
SIPULEUCEL-T is a drug associated with $588,020 in payments to 3 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is Valeant Pharmaceuticals North America LLC.
Payment data is available from 2017 to 2017. In 2017, $588,020 was paid across 5 transactions to 3 doctors.
The most common payment nature for SIPULEUCEL-T is "Unspecified" ($588,020, 100.0% of total).
SIPULEUCEL-T is associated with 4 research studies, including "IISInman-George" ($276,444).